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tributes greatly to the morbidity andmortality in patients with CF.
CF patients have recurrent and chronic respiratory tract infections
andmost of their morbidity andmortality is due to such infections
throughout their life [1,2]. These infections are usually dominated
by non-fermenting Gram-negative organisms (Burkholderia
cenocepacia and Stenotrophomonas maltophilia), including
Pseudomonas aeruginosa. P. aeruginosa is the single most im-
portant pathogen in this patient population. Recent advances in
treatment, which include intensive physiotherapy and aggressive
antibiotic treatment, have greatly improved the outlook for pa-
tients. However, with the improvement in survival rates in CF
patients, a new range of pulmonary issues have arisen. These
include the emergence of multi-drug resistant strains ofP. aerugi-
nosa [3] and the appearance of organisms with increased viru-
lence such as the Burkholderia cepacia complex (BCC).
There are approximately 283 adult CF patients in Northern
Ireland (NI) with CF, where they receive regional CF centre-
based multidisciplinary care at the Regional Adult Cystic
Fibrosis Centre, Belfast City Hospital.⁎ Corresponding author at: Northern Ireland Public Health Laboratory,
Department of Bacteriology, Belfast City Hospital, Belfast BT9 7AD, Northern
Ireland, UK. Tel.: +44 28 9026 3554; fax: +44 28 9026 3991.
E-mail address: jemoore@niphl.dnet.co.uk (J.E. Moore).
1569-1993/$ -see front matter © 2012 European Cystic Fibrosis Society. Published
doi:10.1016/j.jcf.2012.01.002At present, the UK CF Registry, which is compiled by the
CF Trust [4], includes data on the presence of respiratory path-
ogens, but does not include any information on antibiotic
susceptibility of colonising/infection respiratory pathogens, in-
cluding P. aeruginosa. A study was therefore undertaken local-
ly to evaluate current levels of antimicrobial susceptibility in
adult CF patients who were infected with P. aeruginosa and
to compare levels of antibiotic susceptibility, with a comparator
non-CF population of invasive P. aeruginosa, isolated from
blood culture material.
One hundred and twenty seven adult patients (approximately.
61.7% of total adult CF patients in NI) with a confirmed clinical
diagnosis of CF were included in the study. There were 72
males and 55 females, with an age range of 19–82 years and
18–61 years, respectively. Of the 127 patients with a documented
history of P. aeruginosa infection, P. aeruginosa isolates were se-
lected as part of the routinemicrobiological workup, which includ-
ed the selection of isolates which were morphologically different,
including those which were mucoid. From these, 99 were non-
mucoid, 26 were mucoid and 2 were mixed (mucoid+non-
mucoid). Antibiotic susceptibility profiles of the most recent
P. aeruginosa isolate were examined and antibiotic susceptibility
noted against the following four antibiotic classes [11 agents]:
aminoglycosides [amikacin, gentamicin, tobramycin], β-lactams
[aztreonam, ceftazidime, imipenem, meropenem, temocillin,by Elsevier B.V. All rights reserved.
350 Correspondencetazobactam/piperacillin], fluoroquinolones [ciprofloxacin] and
polymyxins [colistin]. Antibiotic susceptibility was recorded as
either susceptible (sensitive) or non-susceptible (moderately
or totally resistant). For comparative purposes, 173 isolates of
P. aeruginosa were examined from a non-CF source, namely
from blood culture material from the period 2001–2009, using
a similar standard disc diffusion assay to that employing in CF
susceptibility testing. - A similar panel of antibiotics with break-
points was employed to the CF panel with the exception of ami-
kacin, temocillin and imipenem, which were not tested in the
non-CF isolates.
Comparison of antibiotic susceptibilities for CF and non-CF
derived P. aeruginosa isolates is shown in Fig. 1. By employ-
ment of the t test, antibiotic susceptibility was statistically sig-
nificantly lower (p=0.0045) in CF-derived isolates than in
non-CF derived P. aeruginosa isolates for all antibiotic classes
and agents examined. Antibiotic resistance in CF isolates to
amikacin, imipenem and temocillin was 52.8%, 43.3% and
37.0%, respectively. Within the CF population of P. aeruginosa
isolates, most antibiotic susceptibility was seen in tazocin/
aztreonam Nceftazidime Nmeropenem N temocillin N imipenem
within the β-lactam agents, with tobramycin Namikacin
Ngentamicin, within the aminoglycoside agents.
Multidrug resistance (i.e. antibiotic non-susceptibility in
two classes of three from aminoglycosides, β-lactams and fluoro-
quinolones) was observed in 19 non-mucoid isolates/pa-
tients (15.0% CF patient population examined), whilst pan-G
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Fig. 1. Comparison of antibiotic susceptibility in eight antibiotic agents from CF-ass
vasive blood culture material.P. aeruginosa from CF sputum (n=127 shaded bars) w
CF (unshaded bars). P. aeruginosa originating from CF sources were significantly m
amples of antibiotics with these classes of antibiotics.resistance (i.e. antibiotic non-susceptibility in all three classes,
aminoglycosides, β-lactams and fluoroquinolones) was observed
in 12 isolates/patients (9.5% CF patient population examined),
with all but one isolate being non-mucoid. Tobramycin, merope-
nem and ciprofloxacin were chosen, as surrogates of the aminogly-
cosides, the cell wall active agents (β-lactams) and the
fluoroquinolones, respectively, as indicated by the Cystic Fibrosis
Foundation [5]. The various combinations and frequency of resis-
tance within these classes of antibiotics are shown (Fig. 2).
In an attempt to display the clustering relationship of these
127 isolates based on antibiotic susceptibilities, we performed
a cluster analysis employing Euclidean distance, i.e.
distance x; yð Þ ¼ Si xi−yið Þ2
n o1=2
which is the geometric distance between points in multidimen-
sional space. For each antibiotic susceptibility datapoint with
each isolate, the qualitative susceptibility profile of susceptible/
non-susceptible was converted to a quantitative score, where
1=susceptible and 2=non-susceptible. The latter category in-
cluded fully resistant, as well as intermediately/moderately resis-
tant phenotypes. A distance matrix spreadsheet was compiled of
all isolates and the similarity displayed on a tree joining dendo-
gram (Fig. 3), employing the multivariate exploratory/cluster
analysis function within the Statistica software package (Stats-
Soft Inc., Tulsa, USA). From this, 31 individual resistotypesTa
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Fig. 2. A Venn diagram showing association between antibiotic susceptibilities
of CF-associated Pseudomonas aeruginosa within three classes of antibiotics,
namely aminoglycosides (tobramycin), β-lactams (meropenem) and the fluoro-
quinolones (ciprofloxacin). Isolates were classified as being either susceptible
(complete sensitivity) or non-susceptible (moderately resistance and fully resis-
tant). Within the Venn diagram circles are 65 isolates representing varying de-
grees of antibiotic resistance, whilst there are 62 isolates outside the Venn
diagram, representing the susceptible isolates. Together, these constitute the en-
tire population of P. aeruginosa isolates examined in this study (i.e. 65+
62=127 isolates).
351Correspondence(i.e. a specific and unique antibiotic susceptibility phenotype
across 11 antibiotic agents) of which resistotype A and resisto-
type B formed the largest clusters, of 18.1% and 8.7%, respec-
tively, of total isolates examined.0.0 0.5 1.0 1.5
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Fig. 3. Cluster analysis based on Euclidean distances relating antibiotic susceptibilit
aeruginosa.In any comparative study, it is important to appreciate the dif-
ferences between the two sets of isolates being compared. The CF
P. aeruginosa isolate examined was the most recent isolate
obtained from each CF patient. In most cases, the CF isolates
were from January to July 2011, but a minority were from
2010, namely whenever the CF patient last presented to either
out-patient clinic or was an in-patient. The isolation methods dif-
fered between the way CF and non-CF (blood culture) isolates
were obtained, as is normal practise in most clinical microbiology
service laboratories. In the case of CF, isolates were cultured di-
rectly from CF sputum by selective plating techniques, namely
on Pseudomonas Isolation Agar, whereas in the case of P. aeru-
ginosa obtained from blood culture, isolates were obtained via
non-selective liquid culture medium (Becton Dickinson BactA-
lert Aerobic culture medium) followed by plating onto non-
selective medium, Columbia Agar Base, supplemented with 5%
[v/v] defibrinated horse blood. Once isolated, both P. aeruginosa
isolates from CF and non-CF were treated in a similar fashion
through identification stages (API 20 NE), as well as through an-
timicrobial susceptibility testing using standardised disc suscepti-
bility testing using CLSI criteria (www.CLSI.org). The number
of antibiotics tested differed between CF and non-CF isolates,
where there was a larger number of antibiotics tested for CF iso-
lates, to aid in antibiotic management decision making, due to the
inherent higher rates of resistance in the CF isolates, in compari-
son with the blood culture P. aeruginosa isolates. Breakpoints
did not change throughout the periods examined. However, we
now wish to report these data as our laboratory is now changing
over to EUCAST breakpoint criteria (www.eucast.org/) and
such a retrospective examination of susceptibility would be
more difficult to perform, hence the timeliness of our manuscript.
It is equally important to differentiate P. aeruginosa from CF
and non-CF sources, given the major differences in antibiotic2.0 2.5 3.0 3.5 
Distance
ies to 11 antibiotic agents amongst 127 isolates of CF-associated Pseudomonas
352 Correspondencesusceptibility data between these two cohorts of P. aeruginosa.
Previously, in such a study, Bosso et al. [6] reported that by com-
bining CF and non-CF isolates, this led to a situation of perceived
overestimating antibiotic resistance in non-CF P. aeruginosa iso-
lates, which could potentially lead to alteration in empirical pre-
scribing in such non-CF cases. Given the relatively small
numbers of P. aeruginosa examined in this study, as well as the
examination of antibiotic susceptibility at a single recent time-
point, it is difficult to reliably attribute increased resistance levels
to use of various antibiotics, in a quantitative and statistically ro-
bust manner. However, during the period examined and prior to
this, most CF patients would have had exposure to the three
major classes of antibiotics, namely the β-lactams, the aminogly-
cosides and the fluoroquinolones. Previously, Manno et al. [7]
examined antibiotic susceptibility patterns in 1315 mucoid
P. aeruginosa isolates from 224 patients, alongside antibiotic
usage data over a five-year period and showed that there was a
significant decline in the susceptibility to the aminoglycosides,
imipenem and ciprofloxacin, while the susceptibility of
P. aeruginosa to piperacillin and ceftazidime was stable.
Overall, this study showed that P. aeruginosa isolated from
patients with CF is more resistant than P. aeruginosa from non-
CF patients. This phenomenon has been shown previously in
CF with other organisms, including Staphylococcus aureus, as
well as the viridans group streptococci [8–10] and reflects the
chronic burden of antibiotic exposure of pathogens and com-
mensal flora to several classes of antibiotics used in the man-
agement of CF airways infection. These data also illustrate
the complexity of antibiotic susceptibility within CF P. aerugi-
nosa, with the generation of at least 31 resistotype profiles from
127 patients. Analyses of resistotype information can lead to
the arbitrary grouping of P. aeruginosa isolates into sensitive,
multidrug resistant (MDR-P. aeruginosa) and pan-resistant
(PR-P. aeruginosa) phenotypes, based on previous definitions
of these terms [11]. In our case, approximately a quarter of
the Pseudomonas clinic are either MDR-P. aeruginosa or PR
P. aeruginosa (15.0% and 9.5%, respectively). Extended ana-
lyses of simple antibiogram information can help elucidate
trends in antibiotic susceptibility, as well as patient profiling
in terms of the resistotype that individual patients harbour,
and help to cohort patients within susceptibility groupings, for
infection control purposes, where epidemic strains with aknown resistotype pattern are circulating within patients at a
CF centre.
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